ZENTALIS PHARMACEUTICA

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

16 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

09 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 سبتمبر 2024 16:40:50 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

09 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أغسطس 2024 18:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 يوليو 2024 18:00:47 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

18 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 يونيو 2024 18:00:55 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

30 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

29 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

23 مايو 2024 17:01:39 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit

14 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

07 مايو 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 مايو 2024 17:30:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

02 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أبريل 2024 17:30:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 مارس 2024 18:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

28 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

27 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference

13 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire